Skip to main content
Top
Published in: Endocrine 3/2021

01-12-2021 | SARS-CoV-2 | Original Article

Finding answers in lipid profile in COVID-19 patients

Authors: M. Sampedro-Nuñez, N. Aguirre-Moreno, L. García-Fraile Fraile, S. Jiménez-Blanco, C. Knott-Torcal, P. Sanz-Martin, G. Fernández-Jiménez, M. Marazuela

Published in: Endocrine | Issue 3/2021

Login to get access

Abstract

Introduction

A small percentage of patients will develop a severe form of COVID-19 caused by SARS-CoV-2 infection. Thus, it is important to predict the potential outcomes identifying early markers of poor prognosis. In this context, we evaluated the association of SARS-CoV-2 infection with lipid abnormalities and their role in prognosis.

Methods

Single-center, retrospective, observational study of COVID-19 patients admitted from March to October 2020. Clinical and laboratory data, comorbidities, and treatments for COVID-19 were evaluated. Main outcomes including intensive care unit (ICU) admission and mortality were analyzed with a multivariable Cox proportional hazards regression model.

Results

We selected 1489 from a total of 2038 consecutive patients with confirmed COVID-19, who had a complete lipid profile before ICU admission. During the follow-up performed in 1109 patients, we observed a decrease in T-c, HDL-c, and LDL-c in 28.6%, 42.9%, and 30.4% of patients, respectively, and an increase in TG in 76.8%. The decrease of both T-c and HDL- c was correlated with a decrease in albumin levels (r = 0.39 and r = 0.37, respectively). Kaplan–Meier survival curves found an increased ICU admission in patients with lower T-c (HR 0.55, CI 0.36–0.86), HDL-c (HR 0.61, CI 0.45–0.84), and LDL-c (HR 0.85, CI 0.74–0.97). Higher values of T-c (HR 0.45, CI 0.36–0.57), HDL-c (HR 0.66, CI 0.54–0.81), and LDL-c (HR 0.86, CI 0.78–0.94) showed a protective effect on mortality.

Conclusions

Abnormalities in lipid profile are a frequent complication of SARS-CoV-2 infection and might be related to morbidity and mortality.

Funding

Proyectos de Investigación en Salud (FIS) and cofinanced by FEDER.
Literature
1.
go back to reference Z. Wu and J. M. McGoogan, Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 323(13), 1239–1242 (2020) Z. Wu and J. M. McGoogan, Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 323(13), 1239–1242 (2020)
2.
go back to reference C. Wang et al. A novel coronavirus outbreak of global health concern. Lancet 395(10223), 470–473 (2020)CrossRef C. Wang et al. A novel coronavirus outbreak of global health concern. Lancet 395(10223), 470–473 (2020)CrossRef
3.
go back to reference M. J. Cummings et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet 395(10239), 1763–1770 (2020) M. J. Cummings et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet 395(10239), 1763–1770 (2020)
4.
go back to reference K. R. Feingold, Lipid and lipoprotein levels in patients with COVID-19 infections. 2000. K. R. Feingold, Lipid and lipoprotein levels in patients with COVID-19 infections. 2000.
5.
go back to reference X. Cao et al. Cholesterol: A new game player accelerating vasculopathy caused by SARS-CoV-2? Am. J. Physiol. Endocrinol. Metab. 319(1), E197–E202 (2020)CrossRef X. Cao et al. Cholesterol: A new game player accelerating vasculopathy caused by SARS-CoV-2? Am. J. Physiol. Endocrinol. Metab. 319(1), E197–E202 (2020)CrossRef
6.
go back to reference M. Escobar and L. Martinez-Uribe, Network coincidence analysis: the netCoin R Package. 2020, 93(11), p. 32. M. Escobar and L. Martinez-Uribe, Network coincidence analysis: the netCoin R Package. 2020, 93(11), p. 32.
7.
go back to reference S. Barlage et al. Changes in HDL-associated apolipoproteins relate to mortality in human sepsis and correlate to monocyte and platelet activation. Intensiv. Care Med. 35(11), 1877–1885 (2009)CrossRef S. Barlage et al. Changes in HDL-associated apolipoproteins relate to mortality in human sepsis and correlate to monocyte and platelet activation. Intensiv. Care Med. 35(11), 1877–1885 (2009)CrossRef
8.
go back to reference J.Y. Chien et al. Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis. Crit. Care Med. 33(8), 1688–1693 (2005)CrossRef J.Y. Chien et al. Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis. Crit. Care Med. 33(8), 1688–1693 (2005)CrossRef
9.
go back to reference A. Lekkou et al. Serum lipid profile, cytokine production, and clinical outcome in patients with severe sepsis. J. Crit. Care 29(5), 723–727 (2014)CrossRef A. Lekkou et al. Serum lipid profile, cytokine production, and clinical outcome in patients with severe sepsis. J. Crit. Care 29(5), 723–727 (2014)CrossRef
10.
go back to reference C. Grunfeld et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J. Clin. Endocrinol. Metab. 74(5), 1045–1052 (1992)PubMed C. Grunfeld et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J. Clin. Endocrinol. Metab. 74(5), 1045–1052 (1992)PubMed
11.
go back to reference J. Oh, R.A. Hegele, HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infect Dis 7(12), 787–796 (2007)CrossRef J. Oh, R.A. Hegele, HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infect Dis 7(12), 787–796 (2007)CrossRef
12.
go back to reference A. R. Rubel, et al. Lipemic serum in patients with Coronavirus Disease 2019 (COVID-19) undergoing treatment. J. Med. Virol. 92(10), 1810–1811 (2020) A. R. Rubel, et al. Lipemic serum in patients with Coronavirus Disease 2019 (COVID-19) undergoing treatment. J. Med. Virol. 92(10), 1810–1811 (2020)
13.
go back to reference A. R. Morrison, et al. Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab. J. Med. Virol. 92(10), 1791–1792 (2020) A. R. Morrison, et al. Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab. J. Med. Virol. 92(10), 1791–1792 (2020)
14.
go back to reference H. Nakamura et al. Acute hypertriglyceridaemia caused by tocilizumab in a patient with severe COVID-19. Intern. Med. 59(22), 2945–2949 (2020)CrossRef H. Nakamura et al. Acute hypertriglyceridaemia caused by tocilizumab in a patient with severe COVID-19. Intern. Med. 59(22), 2945–2949 (2020)CrossRef
15.
go back to reference X. Hu et al. Declined serum high density lipoprotein cholesterol is associated with the severity of COVID-19 infection. Clin. Chim Acta 510, 105–110 (2020)CrossRef X. Hu et al. Declined serum high density lipoprotein cholesterol is associated with the severity of COVID-19 infection. Clin. Chim Acta 510, 105–110 (2020)CrossRef
16.
go back to reference J. Fan et al. Letter to the Editor: low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019. Metabolism 107, 154243 (2020)CrossRef J. Fan et al. Letter to the Editor: low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019. Metabolism 107, 154243 (2020)CrossRef
17.
go back to reference X. Wei et al. Hypolipidemia is associated with the severity of COVID-19. J. Clin. Lipidol. 14(3), 297–304 (2020)CrossRef X. Wei et al. Hypolipidemia is associated with the severity of COVID-19. J. Clin. Lipidol. 14(3), 297–304 (2020)CrossRef
18.
go back to reference G. Wang et al. Low high-density lipoprotein level is correlated with the severity of COVID-19 patients: an observational study. Lipids Health Dis. 19(1), 204 (2020)CrossRef G. Wang et al. Low high-density lipoprotein level is correlated with the severity of COVID-19 patients: an observational study. Lipids Health Dis. 19(1), 204 (2020)CrossRef
19.
go back to reference S. Tanaka et al. Lipoprotein concentrations over time in the intensive care unit COVID-19 patients: results from the ApoCOVID study. PLoS ONE 15(9), e0239573 (2020)CrossRef S. Tanaka et al. Lipoprotein concentrations over time in the intensive care unit COVID-19 patients: results from the ApoCOVID study. PLoS ONE 15(9), e0239573 (2020)CrossRef
20.
go back to reference Q. Zhang et al. Clinical analysis of risk factors for severe COVID-19 patients with type 2 diabetes. J. Diabetes Complicat. 34(10), 107666 (2020)CrossRef Q. Zhang et al. Clinical analysis of risk factors for severe COVID-19 patients with type 2 diabetes. J. Diabetes Complicat. 34(10), 107666 (2020)CrossRef
21.
go back to reference D. Wang et al. Correlation analysis between disease severity and clinical and biochemical characteristics of 143 cases of COVID-19 in Wuhan, China: a descriptive study. BMC Infect. Dis. 20(1), 519 (2020)CrossRef D. Wang et al. Correlation analysis between disease severity and clinical and biochemical characteristics of 143 cases of COVID-19 in Wuhan, China: a descriptive study. BMC Infect. Dis. 20(1), 519 (2020)CrossRef
22.
go back to reference F. Begue et al. Altered high-density lipoprotein composition and functions during severe COVID-19. Sci. Rep. 11(1), 2291 (2021)CrossRef F. Begue et al. Altered high-density lipoprotein composition and functions during severe COVID-19. Sci. Rep. 11(1), 2291 (2021)CrossRef
23.
go back to reference M. Wendel, R. Paul, A.R. Heller, Lipoproteins in inflammation and sepsis. II. Clinical aspects. Intensiv. Care Med. 33(1), 25–35 (2007)CrossRef M. Wendel, R. Paul, A.R. Heller, Lipoproteins in inflammation and sepsis. II. Clinical aspects. Intensiv. Care Med. 33(1), 25–35 (2007)CrossRef
24.
go back to reference A.V. Sorokin et al. COVID-19-associated dyslipidemia: implications for mechanism of impaired resolution and novel therapeutic approaches. FASEB J. 34(8), 9843–9853 (2020)CrossRef A.V. Sorokin et al. COVID-19-associated dyslipidemia: implications for mechanism of impaired resolution and novel therapeutic approaches. FASEB J. 34(8), 9843–9853 (2020)CrossRef
25.
go back to reference Y. Rodriguez, et al. Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. J. Autoimmun. 114, 102506 (2020) Y. Rodriguez, et al. Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. J. Autoimmun. 114, 102506 (2020)
26.
go back to reference W. Huang et al. Decreased serum albumin level indicates poor prognosis of COVID-19 patients: hepatic injury analysis from 2,623 hospitalized cases. Sci. China Life Sci. 63(11), 1678–1687 (2020)CrossRef W. Huang et al. Decreased serum albumin level indicates poor prognosis of COVID-19 patients: hepatic injury analysis from 2,623 hospitalized cases. Sci. China Life Sci. 63(11), 1678–1687 (2020)CrossRef
27.
go back to reference E. Orsi et al. Independent association of atherogenic dyslipidaemia with all-cause mortality in individuals with type 2 diabetes and modifying effect of gender: a prospective cohort study. Cardiovasc. Diabetol. 20(1), 28 (2021)CrossRef E. Orsi et al. Independent association of atherogenic dyslipidaemia with all-cause mortality in individuals with type 2 diabetes and modifying effect of gender: a prospective cohort study. Cardiovasc. Diabetol. 20(1), 28 (2021)CrossRef
28.
go back to reference Y. Gao et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J. Med. Virol. 92(7), 791–796 (2020)CrossRef Y. Gao et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J. Med. Virol. 92(7), 791–796 (2020)CrossRef
29.
go back to reference J. Helms, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study.Intensiv. Care Med. 46(6), 1089–1098 (2020).CrossRef J. Helms, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study.Intensiv. Care Med. 46(6), 1089–1098 (2020).CrossRef
30.
go back to reference Pal, R., et al., Statin use and clinical outcomes in patients with COVID-19: an updated systematic review and meta-analysis. Postgrad. Med. J. (2021) Pal, R., et al., Statin use and clinical outcomes in patients with COVID-19: an updated systematic review and meta-analysis. Postgrad. Med. J. (2021)
Metadata
Title
Finding answers in lipid profile in COVID-19 patients
Authors
M. Sampedro-Nuñez
N. Aguirre-Moreno
L. García-Fraile Fraile
S. Jiménez-Blanco
C. Knott-Torcal
P. Sanz-Martin
G. Fernández-Jiménez
M. Marazuela
Publication date
01-12-2021
Publisher
Springer US
Published in
Endocrine / Issue 3/2021
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-021-02881-0

Other articles of this Issue 3/2021

Endocrine 3/2021 Go to the issue